Business
Research Update: Positive Leukaemia Model Study
Research Update: Positive Leukaemia Model Study.
About this update from Sareum Holdings Plc
[{"type":"text","content":"\n \n\n\n\n\n (AIM: SAR) 7 February 2011\n\n\n SAREUM HOLDINGS PLC\n (\"Sareum\" or the \"Company\")\n\n Research Update: Positive Leukaemia Model Study\nSareum (AIM: SAR), the specialist cancer drug discovery business, is pleased to\nannounce positive results from its pre-clinical in-vivo efficacy studies into\nacute myeloid leukaemia (AML), the most common form of adult leukaemia.\n\nA recent study for Sareum's Aurora+FLT3 Kinase programme showed that the\nleukaemia regressed to such an extent that no detectable cancer could be found\nin any of the cases treated (ten in total) with a Sareum compound. By\ncomparison, leukaemia increased five to fifteen fold in the study examples\ntreated without Sareum's compound. Â At six weeks following treatment, no\ndetectable cancer could be found in two of the ten examples dosed with the\nSareum compound. In the remaining eight treated examples, the average time taken\nfor the leukaemia to increase 5-fold was six weeks, compared to two weeks in the\nuntreated cases.\n\nSareum's CEO, Dr Tim Mitchell, commented: \"The results of Sareum's study compare\nvery favourably with those from similar pre-clinical studies published for\nAurora kinase inhibitors currently undergoing clinical trials. We look forward\nto presenting the data to potential licencees. 350,000 people a year are\ndiagnosed with leukaemia and we are very pleased to be contributing to the\nsearch for a cure for this disease\".\n\n Sareum Holdings plc\n\n Tim Mitchell 01223 497 700\n\n\n\n Merchant Securities Limited (Nomad)\n\n Simon Clements/Bidhi Bhoma 020 7628 2200\n\n\n\n Hybridan LLP (Broker)\n\n Claire Noyce 020 7947 4350\n\n\nNotes for editors:\n\nAbout Sareum Holdings plc\nSareum is a drug discovery company, headquartered in Cambridge UK, that is\nfocused on producing targeted small molecule therapeutics to address unmet\nmedical needs, primarily in cancer. Sareum aims to successfully deliver drug\ncandidates for licensing to pharmaceutical and biotechnology companies at the\npre-clinical or early clinical trials stage.\n\nSareum's Chk1 kinase cancer research programme is a joint research collaboration\nwith The Institute of Cancer Research and Cancer Research Technology Limited.\nNovel chemical compounds developed by the collaboration have been shown to\nincrease the effectiveness of current cancer therapeutics in...